Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Idenix Pharmaceuticals Inc    IDIX   US45166R2040

SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisions 

Idenix Pharmaceuticals Inc : Idenix Announces Data Presentation at the 48th Annual Meeting of the European Association for the Study of the Liver (EASL)

04/08/2013 | 04:47pm US/Eastern
Recommend:
0
Idenix Announces Data Presentation at the 48th Annual Meeting of the European Association for the Study of the Liver (EASL)

CAMBRIDGE, Mass., April 8, 2013 (GLOBE NEWSWIRE) -- Idenix Pharmaceuticals, Inc. (Nasdaq:IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced that it will present data on IDX719, the Company's pan-genotypic HCV NS5A inhibitor, at the 48th Annual Meeting of the European Association for the Study of the Liver (EASL) which is being held April 24 - 28, 2013 in Amsterdam, the Netherlands. Full abstracts can now be viewed at the EASL website at www.easl.eu.

McCarville, et al, "Treatment-Emergent Variants Following 3 Days of Monotherapy with IDX719, a Potent, Pan-Genotypic NS5A Inhibitor, in Subjects Infected with HCV Genotypes 1-4", will be presented in a poster session on Saturday, April 27.

About Idenix

Idenix Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts, is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases. Idenix's current focus is on the treatment of infections caused by hepatitis C virus. For further information about Idenix, please refer to www.idenix.com.

Forward-looking Statements

This press release contains "forward-looking statements" for purposes of the safe harbor provisions of The Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words "expect," "plans," "anticipates," "intends," "will," and similar expressions are also intended to identify forward-looking statements, as are any expressed or implied statements with respect to: the Company's plans to continue to developing nucleotide polymerase inhibitors for HCV; its clinical development plans for its uridine nucleotide analog drug candidate and IDX719; its plans to advance other preclinical nucleotides; and statements regarding the efficacy and safety of its clinical compounds. Actual results may differ materially from those indicated by such forward-looking statements as a result of risks and uncertainties, including but not limited to the following: there can be no guarantees that the Company will advance any clinical product candidate or other component of its potential pipeline to the clinic, to the regulatory process or to commercialization due to numerous risks inherent in pharmaceutical research and development; management's expectations could be affected by unexpected regulatory actions or delays; uncertainties relating to, or unsuccessful results of, preclinical and clinical trials, including additional data relating to the ongoing clinical trials evaluating its product candidates; the Company's ability to obtain additional funding required to conduct its research, development and commercialization activities; competition; and the Company's ability to obtain, maintain and enforce patent and other intellectual property protection for its product candidates and its discoveries. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. These and other risks which may impact management's expectations are described in greater detail under the heading "Risk Factors" in the Company's annual report on Form 10-K for the year ended December 31, 2012, as filed with the Securities and Exchange Commission (SEC) and in any subsequent periodic or current report that the Company files with the SEC.

All forward-looking statements reflect the Company's estimates only as of the date of this release (unless another date is indicated) and should not be relied upon as reflecting the Company's views, expectations or beliefs at any date subsequent to the date of this release. While Idenix may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so, even if the Company's estimates change.

CONTACT: Idenix Pharmaceuticals Contacts:
         Kelly Barry (617) 995-9033 (media)
         Teri Dahlman (617) 995-9807 (investors)
Idenix Pharmaceuticals
distributed by
Recommend :
0
React to this article
Latest news on IDENIX PHARMACEUTICALS INC
04/07 IDENIX PHARMACEUTICALS : Other Events, Financial Statements and Exhibits (form 8..
04/07 IDENIX PHARMACEUTICALS : Announces Promising Clinical Data and Continued Progres..
04/03 IDENIX PHARMACEUTICALS : Change in Directors or Principal Officers (form 8-K)
04/02 Nasdaq stocks posting largest percentage decreases
03/28 IDENIX PHARMACEUTICALS : Assigned Patent
03/24 IDENIX PHARMACEUTICALS : Other Events, Financial Statements and Exhibits (form 8..
03/24 IDENIX PHARMACEUTICALS : Announces Nucleotide Prodrug (IDX21437) and NS5A Inhibi..
03/24 Idenix Pharmaceuticals Intends to Appeal Norway District Court Decision Regar..
03/21 IDENIX PHARMACEUTICALS : Assigned Patent
03/19 INVESTOR'S WATCH LIST – TALISM : TLM), National Bank of Greece(NBG), Orexi..
Advertisement
Chart
Duration : Period :
Idenix Pharmaceuticals Inc Technical Analysis Chart | IDIX | US45166R2040 | 4-Traders
Income Statement Evolution
Idenix Pharmaceuticals Inc : Income Statement Evolution
More Financials
Dynamic quotes  
ON
| OFF